This is an international site for FEMARA^® (letrozole) and is intended for Health Care Professionals outside
the U.S. The information on the site is not country-specific, and may contain information that is outside the
approved indications in the country in which you are located. Please contact your local Novartis
representative for the latest information specific to your country.

The Femara^® International Website For Healthcare Professionals Outside the U.S.

>> For US Residents

>> Country Sites

>> European Summary of Product Characteristics >> Safety Information

Femara | Help keep distant metastases Out of the picture with FEMARA®

Patient Case Studies
BIG 1-98 Challenge
Femara Virtual Exhibit Booth
Country Sites

Home
Femara^® Interactive
Patient Case Studies
Profile Annette

FEMARA^® patient case study #3: Annette

Clinical profile

Age 75
Stage 1
Postmenopausal
Comorbidities:
- Type 2 diabetes
- Osteoarthritis

Breast cancer characteristics

ER+/PR-
T1 (1 cm)
Grade 1
No nodal involvement
HER-2/neu-
Lumpectomy
Radiation

What do you think about Annette's case?

Please click on the most appropriate response.

1. Based on Annette's "low-risk" status, what is her risk for distant metastases?
<5% 11% 20%

2. If Annette developed distant metastases as a first recurrence, what is her risk of mortality within 5 years?
Nearly 1 in 3 Nearly 4 in 5 Nearly 5 in 10

3. What treatment protocol would you use for Annette?
Tamoxifen for 5 years
Tamoxifen for 5 years, then an aromatase inhibitor (AI)
Initial adjuvant therapy with any AI
None of the above

Disclaimer: This is an international website for Femara^® (letrozole) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About Novartis Oncology
Site Map
Safety
Privacy Policy
Contact Us
Help

FEMARA® patient case study #3: Annette

Clinical profile

Breast cancer characteristics

What do you think about Annette's case?

FEMARA^® patient case study #3: Annette